波纳提尼布用于治疗急性淋巴细胞白血病
Tamer Othman1, Dat Ngo1, Jose Tinajero1
1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
Future oncology (London, England)
|November 14, 2025
概括
波纳替尼 (ponatinib) 是一种强效的氨酸激酶抑制剂 (TKI),已经改变了费城染色体阳性急性淋巴细胞白血病 (Ph+ ALL) 的治疗方法. 它显著改善了结果和生存率,为新诊断的成年患者建立了新的护理标准.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 费城染色体阳性急性淋巴细胞白血病 (Ph+ ALL) 历史上预后不佳.
- 氨酸激酶抑制剂 (TKIs) 已经彻底改变了Ph+ALL治疗,提高了反应率和生存率.
- 全基性造血细胞移植 (HCT) 改善了结果,但并不总是可行的或足够的.
研究的目的:
- 审查评估ponatinib用于新诊断的Ph + ALL的里程碑性试验.
- 要总结ponatinib在这个患者群体中的疗效和毒性概况.
- 确立ponatinib作为医疗适合的成年患者的护理标准.
主要方法:
- 对临床试验的审查,重点是Ponatinib在Ph+ALL.
- 对疗效数据的分析,包括反应率和生存结果.
- 评估与ponatinib治疗相关的毒性概况和安全数据.
主要成果:
- 波纳替尼 (ponatinib) 是第三代TKI,表现出卓越的功效,并克服了耐药性突变.
- 临床研究表明,波纳替尼在实现可测量的残留疾病 (MRD) 消极性方面具有优越性.
- 使用波纳替尼,即使没有整合性HCT,也观察到出色的长期生存结果.
结论:
- 波纳替尼已经成功地被整合到各种化疗和布利纳图马布治疗方案中,用于成人Ph+ALL.
- 里程碑式的试验证实了ponatinib的疗效和可接受的毒性概况.
- 波纳替尼 (Ponatinib) 已被确立为新诊断的Ph+ ALL医疗适合患者的标准护理.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
421
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
421
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
543
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
543


